切换导航
  • 比较产品
我的购物车

STEMdiff™ 心肌细胞扩增试剂盒

用于扩增早期人PSC衍生心肌细胞的无血清试剂盒
率先评论此产品
添加并比较

产品号 #（选择产品）

产品号 #100-1109_C

用于扩增早期人PSC衍生心肌细胞的无血清试剂盒

产品优势

  • 通过简单易行的工作流程扩大心肌细胞产量
  • 将 hPSC 衍生的心房肌或心室肌细胞扩增最多 70 倍
  • 生成功能齐全的 hPSC 衍生心肌细胞，用于下游检测
  • 生产纯度超过90%的心肌细胞

产品组分包括

  • STEMdiff™ 心肌细胞扩增试剂盒（目录号 #100-1109）
    • STEMdiff™ 心肌细胞维持基础培养基，1 x 490 mL
    • STEMdiff™ 心肌细胞传代补充剂（100X），1 x 2.5 mL
    • STEMdiff™ 心肌细胞扩增补充剂（50X），1 x 10 mL
main product photo
总览
实验数据
产品说明书及文档
应用领域
相关材料与文献
相关产品

总览

使用该无血清试剂盒，可稳定扩增早期人类多能干细胞 (hPSC) 衍生的心肌细胞。该试剂盒可生成大量功能性且高纯度 hPSC 衍生心肌细胞，并与分别使用STEMdiff™ 心室心肌细胞分化试剂盒或STEMdiff™ 心房心肌细胞分化试剂盒生成的心室肌细胞或心房肌细胞兼容。与传统方法需要先扩增大量 hPSC，再进行多轮分化才能获得大量 hPSC 衍生心肌细胞的方法相比，STEMdiff™ 心肌细胞扩增试剂盒只需通过一轮心肌细胞分化即可扩增早期 hPSC 衍生心肌细胞，轻松获得数十亿个心肌细胞。使用该试剂盒扩增的早期hPSC衍生心肌细胞可保持稳定的电生理特性，并且在第5代时cTnT百分比超过90%。扩增后的hPSC衍生心肌细胞可用于高通量药物测试、组织工程和再生医学研究。

使用这款首创的试剂盒高效扩增心肌细胞，您可以节省时间和资源。

使用以下兼容的STEMdiff™心肌细胞产品创建完整、优化的工作流程：

STEMdiff™心室肌细胞分化试剂盒

STEMdiff™心房肌细胞分化试剂盒

STEMdiff™心肌细胞解离试剂盒

STEMdiff™心肌细胞支持培养基

STEMdiff™心肌细胞冻存培养基

STEMdiff™心肌细胞维持试剂盒

细胞类型
心肌细胞，PSC衍生
 
种属
人
 
应用
分化，扩增
 
品牌
STEMdiff
 
研究领域
疾病建模，药物发现和毒理检测，干细胞生物学，细胞治疗开发
 
制剂类别
无血清
 

查看更多 显示更少

Data Figures

hPSC-derived cardiomyocyte expansion using STEMdiff™ kits. Beating monolayer seen after 11 days.

Figure 1. Workflow for the Expansion of Early-Stage hPSC-Derived Cardiomyocytes Using the STEMdiff™ Cardiomyocyte Expansion Kit

Expansion of early-stage human pluripotent stem cell (hPSC)-derived cardiomyocytes begins with the differentiation of hPSCs to cardiomyocytes using the STEMdiff™ Ventricular Cardiomyocyte Differentiation Kit or the STEMdiff™ Atrial Cardiomyocyte Differentiation Kit. On Day 11 of differentiation, a beating, confluent monolayer of early-stage cardiomyocytes can be observed. These cardiomyocytes are harvested and replated at low density to initiate expansion using STEMdiff™ Cardiomyocyte Expansion Kit. Expanding hPSC-derived cardiomyocytes can be passaged up to 5 times before switching to STEMdiff™ Cardiomyocyte Maintenance Medium for downstream assays.

Representative images: Expansion of ventricular cardiomyocytes using STEMdiff™ Passaging Medium.

Figure 2. Expanding hPSC-Derived Cardiomyocytes Are Confluent One Week After Replating with STEMdiff™ Cardiomyocyte Expansion Kit

Representative images of expanding hPSC-derived ventricular cardiomyocytes after replating at low density (Day 1) using STEMdiff™ Cardiomyocyte Passaging Medium. Cardiomyocyte confluency increases during the 7 day expansion period. On Day 7, a confluent monolayer of beating hPSC-derived cardiomyocytes is observed and the expanded hPSC-derived cardiomyocytes are ready for harvest.

Expansion of hPSC-Derived Cardiomyocytes Across Multiple Cell Lines with STEMdiff™ Cardiomyocyte Expansion Kit

Figure 3. Expansion of hPSC-Derived Cardiomyocytes Across Multiple Cell Lines with STEMdiff™ Cardiomyocyte Expansion Kit

(A) Expansion of hPSC-derived cardiomyocytes was tracked for 5 passages with 4 hPSC lines. Per passage, fold expansion is typically highest in the first 1 – 2 passages. (B) Cumulative fold expansion over 5 passages ranged from 33- to 103-fold expansion and averaged at 72-fold ± 12 (n = 15, 4 hPSC lines).

Cardiomyocyte purity tracked during expansion with STEMdiff™ Expansion Kit. High cTnT expression, 90% purity after 5 passages.

Figure 4. Cardiomyocyte Purity Increases During Expansion Using STEMdiff™ Cardiomyocyte Expansion Kit

Cardiomyocyte purity was tracked during expansion using STEMdiff™ Cardiomyocyte Expansion Kit for 5 passages on 4 hPSC lines. Throughout expansion, hPSC-derived cardiomyocytes express high levels of cardiac troponin T, and on average show an increase in cardiomyocyte purity during expansion. After 5 passages, cardiomyocyte cultures show an average cTnT purity of 90% ± 2% (n = 15).

MEA recordings of post-expanded hPSC-derived cardiomyocytes using STEMdiff™ kits. Stable beat rate observed.

Figure 5. Post-Expanded hPSC-Derived Cardiomyocytes Exhibit Typical Cardiac Electrophysiology and a Stable Beat Profile

Microelectrode Array (MEA) recordings of post-expanded hPSC-derived cardiomyocytes (using STEMdiff™ Cardiomyocyte Expansion Kit) exhibit a stable beat rate across 4 hPSC lines. The post-expanded hPSC-derived cardiomyocytes were replated onto MEA and maintained in STEMdiff™ Cardiomyocyte Maintenance Medium for 1 week. The average beat rate was 12 ± 1 beats per minute (n = 14, 4 hPSC lines).

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet
Product Name
STEMdiff™ Cardiomyocyte Expansion Kit
Catalog #
100-1109
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
STEMdiff™ Cardiomyocyte Expansion Kit
Catalog #
100-1109
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
STEMdiff™ Cardiomyocyte Expansion Kit
Catalog #
100-1109
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Research Area
Workflow Stages

更多信息

更多信息
Species Human
Formulation Category Serum-Free
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。